Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England

Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis,...

Full description

Bibliographic Details
Main Authors: Kuo, Chang-Fu, Grainge, Matthew J., Mallen, Christian, Zhang, Weiya, Doherty, Michael
Format: Article
Published: American Medical Association 2014
Online Access:https://eprints.nottingham.ac.uk/35899/
_version_ 1848795186203721728
author Kuo, Chang-Fu
Grainge, Matthew J.
Mallen, Christian
Zhang, Weiya
Doherty, Michael
author_facet Kuo, Chang-Fu
Grainge, Matthew J.
Mallen, Christian
Zhang, Weiya
Doherty, Michael
author_sort Kuo, Chang-Fu
building Nottingham Research Data Repository
collection Online Access
description Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription.
first_indexed 2025-11-14T19:28:05Z
format Article
id nottingham-35899
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:28:05Z
publishDate 2014
publisher American Medical Association
recordtype eprints
repository_type Digital Repository
spelling nottingham-358992020-05-04T16:58:24Z https://eprints.nottingham.ac.uk/35899/ Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England Kuo, Chang-Fu Grainge, Matthew J. Mallen, Christian Zhang, Weiya Doherty, Michael Gout is caused by urate crystal deposition secondary to persistent hyperuricemia. Current guidelines recommend urate-lowering treatment to prevent crystal deposition and encourage crystal dissolution for patients with more severe gout or concomitant conditions.1,2 However, after the first diagnosis, it remains unclear when such treatment is appropriate. We investigated the timing of eligibility for and prescription of urate-lowering treatment following first gout diagnosis and factors associated with prescription. American Medical Association 2014-12-24 Article PeerReviewed Kuo, Chang-Fu, Grainge, Matthew J., Mallen, Christian, Zhang, Weiya and Doherty, Michael (2014) Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. Journal of the American Medical Association, 312 (24). pp. 2684-2686. ISSN 0098-7484 http://jama.jamanetwork.com/article.aspx?articleid=2084879 doi:10.1001/jama.2014.14484 doi:10.1001/jama.2014.14484
spellingShingle Kuo, Chang-Fu
Grainge, Matthew J.
Mallen, Christian
Zhang, Weiya
Doherty, Michael
Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title_full Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title_fullStr Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title_full_unstemmed Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title_short Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England
title_sort eligibility for and prescription of urate-lowering treatment in patients with incident gout in england
url https://eprints.nottingham.ac.uk/35899/
https://eprints.nottingham.ac.uk/35899/
https://eprints.nottingham.ac.uk/35899/